Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy
AuthorCheah, CY; Hofman, MS; Dickinson, M; Wirth, A; Westerman, D; Harrison, SJ; Burbury, K; Wolf, M; Januszewicz, H; Herbert, K; ...
Source TitleBRITISH JOURNAL OF CANCER
PublisherNATURE PUBLISHING GROUP
University of Melbourne Author/sCarney, Dennis; Westerman, David; Seymour, John; Ritchie, David; Wirth, Andrew; Hofman, Michael; Prince, Henry; Wolf, Mieczyslaw; Harrison, Simon; Hicks, Rodney; ...
AffiliationMedicine, Dentistry & Health Sciences
Melbourne Medical School
Eastern Hill Academic Centre
Medicine (St Vincent's)
Medicine (RMH Academic Centre)
Sir Peter MacCallum Department of Oncology
Document TypeJournal Article
CitationsCheah, C. Y., Hofman, M. S., Dickinson, M., Wirth, A., Westerman, D., Harrison, S. J., Burbury, K., Wolf, M., Januszewicz, H., Herbert, K., Prince, H. M., Carney, D. A., Ritchie, D. S., Hicks, R. J. & Seymour, J. F. (2013). Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. BRITISH JOURNAL OF CANCER, 109 (2), pp.312-317. https://doi.org/10.1038/bjc.2013.338.
Access StatusOpen Access
Open Access at PMChttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3721385
BACKGROUND: The usefulness of positron emission tomography with computed tomography (PET-CT) in the surveillance of patients with diffuse large B-cell lymphoma (DLBCL) in complete metabolic remission after primary therapy is not well studied. METHODS: We performed a retrospective review of our database between 2002 and 2009 for patients with de novo DLBCL who underwent surveillance PET-CT after achieving complete metabolic response (CMR) following primary therapy. RESULTS: Four-hundred and fifty scans were performed in 116 patients, with a median follow-up of 53 (range 8-133) months from completion of therapy. Thirteen patients (11%) relapsed: seven were suspected clinically and six were subclinical (all within first 18 months). The positive predictive value in patients with international prognostic index (IPI) <3 was 56% compared with 80% in patients with IPI ≥3. Including indeterminate scans, PET-CT retained high sensitivity 95% and specificity 97% for relapse. CONCLUSION: Positron emission tomography with computed tomography is not useful in patients for the majority of patients with diffuse large B-cell lymphoma in CMR after primary therapy, with the possible exception of patients with baseline IPI ≥3 in the 18 months following completion of primary therapy. This issue could be addressed by a prospective clinical trial.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References
- Medicine, Dentistry & Health Sciences Collected Works - Research Publications 
- Melbourne Medical School Collected Works - Research Publications 
- Clinical Pathology - Research Publications 
- Eastern Hill Academic Centre - Research Publications 
- Medicine (St Vincent's) - Research Publications 
- Medicine (RMH Academic Centre) - Research Publications 
- Medicine (RMH) - Research Publications 
- Sir Peter MacCallum Department of Oncology - Research Publications